The impact of SF3B1 mutations in CLL on the DNA-damage response

Leukemia

Volumn 29, Issue 5, 2015, Pages 1133-1142

  Te Raa, G D ^a,b   Derks, I A M ^b   Navrkalova, V ^c   Skowronska, A ^d   Moerland, P D ^a   Van Laar, J ^a,b   Oldreive, C ^d   Monsuur, H ^b   Trbusek, M ^c   Malcikova, J ^c   Loden M ^e   Geisler, C H ^f   Hullein J ^g   Jethwa, A ^g   Zenz, T ^g,h   Pospisilova, S ^c   Stankovic, T ^d   Van Oers, M H J ^a,i   Kater, A P ^a,i   Eldering, E ^b,i  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MASARYK UNIVERSITY   (Czech Republic)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e MRC HOLLAND   (Netherlands)

^f Rigshospitalet   (Denmark)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ Lymphoma and Myeloma Center (LYMMCARE)   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; DOXORUBICIN; FAS ANTIGEN; FDXR PROTEIN; FLUDARABINE; HISTONE H2AX; NOTCH1 RECEPTOR; NUTLIN 3; PCNA PROTEIN; PROTEIN; PROTEIN BAX; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; SF3B1 PROTEIN; UNCLASSIFIED DRUG; ATM PROTEIN, HUMAN; H2AFX PROTEIN, HUMAN; HISTONE; IMIDAZOLE DERIVATIVE; NOTCH1 PROTEIN, HUMAN; PHOSPHOPROTEIN; PIPERAZINE DERIVATIVE; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; TP53 PROTEIN, HUMAN; VIDARABINE;

ALLELE; APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; UPREGULATION; ANALOGS AND DERIVATIVES; COHORT ANALYSIS; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; HUMAN GENOME; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS;

APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; COHORT STUDIES; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; DOXORUBICIN; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION REGULATION, LEUKEMIC; GENOME, HUMAN; HISTONES; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PHOSPHOPROTEINS; PIPERAZINES; PROGNOSIS; RECEPTOR, NOTCH1; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; TUMOR SUPPRESSOR PROTEIN P53; VIDARABINE;

EID: 84929291816     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.318     Document Type: Article

References (54)

1. Austen B, Powell JE, Alvi A, Edwards I, Hooper L, Starczynski J et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005; 106: 3175-3182.
2. Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 4473-4479.
3. Zenz T, Habe S, Denzel T, Mohr J, Winkler D, Buhler A et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114: 2589-2597.
4. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208: 1389-1401.
5. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-105.
6. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012; 44: 47-52.
7. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365: 2497-2506.
8. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
9. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011; 118: 6904-6908.
10. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119: 521-529.
11. Domenech E, Gomez-Lopez G, Gzlez-Pena D, Lopez M, Herreros B, Menezes J et al. New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing. PLoS ONE 2012; 7: e38158.
12. Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015; 29: 329-336.
13. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
14. Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, Travaglino E et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011; 118: 6239-6246.
15. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
16. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26: 542-545.
17. Stephens PJ, Tarpey PS, Davies H, Van LP, Greenman C, Wedge DC et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486: 400-404.
18. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu KS, Jerez A et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119: 3203-3210.
19. Visconte V, Makishima H, Maciejewski JP, Tiu RV. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia 2012; 26: 2447-2454.
20. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010; 24: 2343-2364.
21. Golan-Gerstl R, Cohen M, Shilo A, Suh SS, Bakacs A, Coppola L et al. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res 2011; 71: 4464-4472.
22. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007; 8: 349-357.
23. Dreger P, Schnaiter A, Zenz T, Bottcher S, Rossi M, Paschka P et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood 2013; 121: 3284-3288.
24. Geisler CH, van T, Veer MB, Jurlander J, Walewski J, Tjonnfjord G, Itala RM et al. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood 2014; 123: 3255-3262.
25. Kater AP, Spiering M, Liu RD, Beckers MM, Tonino SH, Daenen SMGJ et al. The broad kinase inhibitor dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. Leukemia Res 2013; 38: 34-41.
26. Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MH et al. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 2005; 19: 427-434.
27. Jethwa A, Hullein J, Stolz T, Blume C, Sellner L, Jauch A et al. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. Br J Haematol 2013; 163: 496-500.
28. Navrkalova V, Sebejova L, Zemanova J, Kminkova J, Kubesova B, Malcikova J et al. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin. Haematologica 2013; 98: 1124-1131.
29. Kater AP, Evers LM, Remmerswaal EB, Jaspers A, Oosterwijk MF, van Lier RA et al. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 2004; 127: 404-415.
30. Stankovic T, Hubank M, Cronin D, Stewart GS, Fletcher D, Bignell CR et al. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinghuished by major differences in activating prosurvival responses. Blood 2004; 103: 291-300.
31. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814-822.
32. nd edn. Chapman & Hall: Boca Raton, 2011.
33. Stankovic T, Stewart GS, Fegan C, Biggs P, Last J, Byrd PJ et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002; 99: 300-309.
34. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108: 993-1000.
35. Ziv Y, Bielopolski D, Galanty Y, Lukas C, Taya Y, Schultz DC et al. Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway. Nat Cell Biol 2006; 8: 870-876.
36. Riballo E, Kuhne M, Rief N, Doherty A, Smith GC, Recio MJ et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell 2004; 16: 715-724.
37. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999; 146: 905-916.
38. Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M et al. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med 2013; 5: 189ra78.
39. Kaida D, Schneider-Poetsch T, Yoshida M. Splicing in oncogenesis and tumor suppression. Cancer Sci 2012; 103: 1611-1616.
40. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M et al. Nat Chem Biol 2007; 3: 570-575.
41. Brown PJ, Ashe SL, Leich E, Burek C, Barrans S, Fenton JA et al. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 2008; 111: 2816-2824.
42. Ferreira PG, Jares P, Rico D, Gomez-Lopez G, Martinez-Trillos A, Villamor N et al. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res 2013; 24: 212-226.
43. Adamson B, Smogorzewska A, Sigoillot FD, King RW, Elledge SJ. A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. Nat Cell Biol 2012; 14: 318-328.
44. Beli P, Lukashchuk N, Wagner SA, Weinert BT, Olsen JV, Baskcomb L et al. Proteomic investigations reveal a role for RNA processing factor THRAP3 in the DNA damage response. Mol Cell 2012; 46: 212-225.
45. Paulsen RD, Soni DV, Wollman R, Hahn AT, Yee MC, Guan A et al. A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. Mol Cell 2009; 35: 228-239.
46. Marechal A, Li JM, Ji XY, Wu CS, Yazinski SA, Nguyen HD et al. PRP19 transforms into a sensor of RPA-ssDNA after DNA damage and drives ATR activation via a ubiquitin-mediated circuitry. Mol Cell 2014; 53: 235-246.
47. Wan L, Huang J. The PSO4 complex associates with RPA and modulates the activation of ATR. J Biol Chem 2014; 289: 6619-6626.
48. Savage KI, Gorski JJ, Barros EM, Irwin GW, Manti L, Powell AJ et al. Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability. Mol Cell 2014; 54: 445-459.
49. Wongsurawat T, Jenjaroenpun P, Kwoh CK, Kuznetsov V. Quantitative model of R-loop forming structures reveals a novel level of RNA-DNA interactome complexity. Nucleic Acids Res 2012; 40: e16.
50. Wang C, Chua K, Seghezzi W, Lees E, Gozani O, Reed R. Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev 1998; 12: 1409-1414.
51. Wu X, Tschumper RC, Jelinek DF. Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells. Leukemia 2013; 27: 2264-2267.
52. Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012; 120: 3173-3186.
53. Skowronska A, Parker A, Ahmed G, Oldreive C, Davis Z, Richards S et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol 2012; 30: 4524-4532.
54. Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121: 1403-1412.